Malarone 250mg/100mg Tablets (UK)

Malarone (Atovaquone 250mg/Proguanil 100mg) Tablets are used to prevent malaria in certain regions of the world. Each Malarone tablet contains the two active ingredients Atovaquone 250mg and Proguanil 100mg.

The choice of antimalarial changes periodically and can vary within different regions of the same country. Please check which anti-malaria product is currently needed for your particular destination(s) by clicking HERE , where you will be able to access current advice.

If you are still unsure then you can complete the Malaria Enquiry Form.

A prescription is needed to purchase Malarone tablets. If you don't have a prescription click HERE or on the GREEN banner above 'Buy Now....' where you can access a free and confidential online consultation with a UK registered doctor. The Malarone medication could be with you as early as tomorrow. (Please tell the Pharmadoctor team if you are on a tight schedule.)

Totalpharmacy.co.uk only supply the UK product made by Glaxo SmithKline.

Totalpharmacy.co.uk are a UK registered online Pharmacy.

To prevent malaria in adults:

The standard dose for adults is 1 Malarone tablet once a day, taken as below.

• start taking Malarone 1 to 2 days before travelling to an area which has malaria
• continue taking it every day during your stay
• continue taking it for another 7 days after your return to a malaria-free area.

Not suitable for children. See Malarone Paediatic tablets

Active ingredients: Each Malarone tablet contains 250 mg of atovaquone and 100 mg of proguanil hydrochloride.

Keep out of reach of children.

The safety and effectiveness of Malarone (atovaquone 250 mg/proguanil hydrochloride 100 mg tablets) for prevention of malaria in patients who weigh less than 40kg has not been established.

Persons taking Malarone for prophylaxis or treatment of malaria should take a repeat dose if they vomit within 1 hour of dosing. In the event of diarrhoea, normal dosing should be continued. Absorption of atovaquone may be reduced in patients with diarrhoea or vomiting, but diarrhoea or vomiting was not associated with reduced efficacy in clinical trials of Malarone for malaria prophylaxis. However, as with other antimalarial agents, subjects with diarrhoea or vomiting should be advised to continue to comply with personal protection measures (repellants, bednets).

In patients with acute malaria who present with diarrhoea or vomiting, alternative therapy should be considered. If Malarone is used to treat malaria in these patients, parasitaemia should be closely monitored.

The safety and effectiveness of Malarone (atovaquone 250 mg/proguanil hydrochloride 100 mg tablets) for treatment of malaria in paediatric patients who weigh less than 11 kg has not been established.

Malarone has not been evaluated for the treatment of cerebral malaria or other severe manifestations of complicated malaria including hyperparasitaemia, pulmonary oedema or renal failure.

Occasionally, severe allergic reactions (including anaphylaxis) have been reported in patients taking Malarone. If patients experience an allergic reaction Malarone should be discontinued promptly and appropriate treatment initiated.

Parasite relapse occurred commonly when P. vivax malaria was treated with Malarone alone. Travellers with intense exposure to P. vivax or P. ovale, and those who develop malaria caused by either of these parasites, will require additional treatment with a drug that is active against hypnozoites.

In the event of recrudescent infections due to P. falciparum after treatment with Malarone, or failure of chemoprophylaxis, patients should be treated with a different blood schizonticide.

Parasitaemia should be closely monitored in patients receiving concurrent metoclopramide or tetracycline.

The concomitant administration of Malarone and rifampicin or rifabutin is not recommended.

In patients with severe renal impairment (creatinine clearance <30 mL/min) alternatives to Malarone for treatment of acute P. falciparum malaria should be recommended whenever possible.